
Abzena Appoints Geoffrey M. Glass As Chief Executive Officer
"Over the past few years Abzena has made incredible progress driving operational execution and strengthening our unique scientific capabilities, the combination of which has resulted in delighting many of our customers," said Mr. Glass. "Those efforts have also led to significant growth. I have had the privilege of working alongside this team as Chairman, and I am honored to join as CEO to help continue our momentum. I look forward to working even more closely with our talented employee partners to support our customers and, most importantly, their patients."
In a statement, the Board of Directors said, "Geoff has been a steady and strategic leader as Chairman over the past several years. His deep experience, operational focus, customer-centricity and strong understanding of the business make him the right person to lead Abzena in its next phase. The company is well positioned, and we are confident in Geoff's ability to build on the progress that has already been made."
About Abzena
Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA , Bristol, PA , and Cambridge, UK . Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. Learn more at abzena .
Photo -
SOURCE Abzena

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Tappalpha's Flagship ETF, TSPY, Surpasses $100 Million In AUM
- Schoenherr Opens London Liaison Office As Gateway To Central Eastern Europe
- Daytrading Publishes New Study Showing 70% Of Viral Finance Tiktoks Are Misleading
- Forex Expo Dubai 2025 Conference To Feature 150+ Global FX And Fintech Leaders
- Falcon Finance Unveils $FF Governance Token In Updated Whitepaper
- Edgen Launches Multi‐Agent Intelligence Upgrade To Unify Crypto And Equity Analysis
Comments
No comment